Samsung Biologics said Wednesday that it recorded sales of 1.1 trillion won ($995.9 million) in 2020, up 66 percent from 2019. The company also registered 292.8 billion won in operating profit, up a drastic 219.3 percent over the cited period.

"The company has managed to exceed 1 trillion won in annual sales nine years after its establishment in April 2011," the company said. "Samsung Biologics' sales increased about 12 times in 2020 compared to 2015, when the company started to generate sales in earnest."

The annual average increase in sales during the five years reached 66.4 percent, the company added.

The company stressed that the increase in sales was mainly due to its increased order-taking capabilities through rapid response, such as supporting due diligence and inspection by global regulatory agencies through non-face-to-face real-time virtual tours, despite the difficult environment caused by the Covid-19 pandemic.

"Such efforts helped the company achieve its highest quarterly performance ever in the fourth quarter last year," the company said. "To continue its growth, Samsung Biologics plans to focus its capacity on early receiving orders for production at its fourth plant, scheduled to open in 2023."